Trametinib

 (truh-MEH-tih-nib dy-MEH-thul sul-FOK-side)

This page contains brief information about trametinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Mekinist
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Trametinib is approved to be used alone or with dabrafenib to treat:

Trametinib is used only in patients whose cancer has a certain mutation in the BRAF gene.

Trametinib is also being studied in the treatment of other types of cancer.

More About Trametinib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Trametinib - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer

Two-Drug Combination Approved for Lung Cancers with BRAF Mutations

Combining Two Types of Targeted Therapy Improves Survival in Some Patients With Advanced Melanoma

New Therapies Are Changing the Outlook for Advanced Melanoma

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Trametinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted: June 21, 2013
  • Updated: May 30, 2018